公开(公告)号：WO1998001464A1

公开(公告)日：1998-01-15

申请号：PCT/US1996020034

申请日：1996-12-20

Applicant: AMERICAN NATIONAL RED CROSS ,  KENT, Randall, S. ,  DROHAN, William, N.

Inventor： AMERICAN NATIONAL RED CROSS

IPC: C07K01/22

CPC classification number: C12N9/644 ,  A61K35/14 ,  A61K35/16 ,  C07K1/22 ,  C12Y304/21022

Abstract: The present invention pertains to improved methods for the selective separation of organic components from biological fluids. More particularly, the present invention pertains to methods for the selective separation of organic components from biological fluids which comprise the step of contacting the biological fluid with a synthetic hydrated alkaline earth silicate (i.e., SHAES), such as synthetic hydrated calcium silicate (i.e., SHCS or synthetic hydrated magnesium silicate (i.e., SHMS). In a preferred embodiment, the present invention pertains to such methods where the biological fluid is a mammalian blood fluid (e.g., whole blood, blood plasma, blood serum, blood fraction, plasma fraction, serum fraction).

Abstract translation: 本发明涉及用于从生物流体中选择性分离有机组分的改进方法。 更具体地，本发明涉及从生物流体中选择性分离有机组分的方法，其包括使生物流体与合成的水合碱土金属硅酸盐（即SHAES）接触的步骤，例如合成的水合硅酸钙（即， SHCS或合成水合硅酸镁（即SHMS）在优选的实施方案中，本发明涉及生物流体是哺乳动物血液流体（例如，全血，血浆，血清，血液分数，血浆级分 ，血清分数）。

公开(公告)号：WO1998028325A1

公开(公告)日：1998-07-02

申请号：PCT/US1997023428

申请日：1997-12-19

Applicant: EMORY UNIVERSITY

Inventor： EMORY UNIVERSITY ,  HAGEDORN, Curt, H. ,  SPIVAK-KROIZMAN, Taly ,  XIE, Yiping

IPC: C07K01/22

CPC classification number: C07K14/4705

Abstract: The invention provides a method of purifying human eIF-4E protein and amino acid sequence variants thereof having altered binding affinity for capped RNA. Using the described purification, amino acid sequence variants can readily be expressed, purified and tested. Both lowered and enhanced binding affinity variants are useful for modifying protein expression levels in vivo and in vitro.

Abstract translation: 本发明提供了一种纯化人eIF-4E蛋白质的方法，其具有对加帽RNA具有改变的结合亲和力的氨基酸序列变体。 使用所述纯化，氨基酸序列变体可以容易地进行表达，纯化和测试。 降低和增强的结合亲和力变体都可用于体内和体外修饰蛋白质表达水平。

公开(公告)号：WO1997005159A2

公开(公告)日：1997-02-13

申请号：PCT/EP1996003144

申请日：1996-07-17

Applicant: CIBA-GEIGY AG ,  FAUQUEX, Pierre, François ,  GEORGES, Catherine

Inventor： CIBA-GEIGY AG

IPC: C07K01/22

CPC classification number: C12N9/2417 ,  C07K1/22 ,  C07K14/56 ,  C12N9/6427 ,  Y10S530/811 ,  Y10S530/812

Abstract: The instant invention relates to a new method for the purification of proteins using copper chelate-affinity chromatography, wherein the impure or pre-purified protein is adsorbed on immobilized copper(II) ions, optionally washed with buffer and deionized water, washed with a solution of a Lewis-base, and finally eluted with deionized water.

Abstract translation: 本发明涉及使用铜螯合亲和层析纯化蛋白质的新方法，其中不纯的或预纯化的蛋白质被吸附在固定的铜（II）离子上，任选地用缓冲液和去离子水洗涤，用溶液洗涤 的路易斯碱，最后用去离子水洗脱。

公开(公告)号：WO1995013288A1

公开(公告)日：1995-05-18

申请号：PCT/US1994012985

申请日：1994-11-10

Applicant: THE BOARD OF TRUSTEES FOR THE LELAND STANFORD JUNIOR UNIVERSITY

Inventor： THE BOARD OF TRUSTEES FOR THE LELAND STANFORD JUNIOR UNIVERSITY ,  CLAYBERGER, Carol ,  KRENSKY, Alan, M.

IPC: C07K01/22

CPC classification number: G01N33/56977 ,  A61K38/00 ,  C07K14/705

Abstract: p74 is a protein found in T-cells and other cells, which when bound with specific agents results in inhibition of cytolytic activity and differentiation of CTLs. p74 can be isolated from T-cells and other cells using palindromic HLA-B2702.84-75-84 peptide by affinity binding of a cell lysate.

Abstract translation: p74是在T细胞和其他细胞中发现的蛋白质，当与特异性试剂结合导致CTL的细胞溶解活性和分化的抑制。 可以通过细胞裂解物的亲和结合使用回文HLA-B2702.84-75-84肽从T细胞和其它细胞中分离p74。

公开(公告)号：WO1998006739A1

公开(公告)日：1998-02-19

申请号：PCT/US1997014487

申请日：1997-08-18

Applicant: CLONTECH LABORATORIES, INC.

Inventor： CLONTECH LABORATORIES, INC. ,  NELSON, Paul, S. ,  YANG, Te-Tuan ,  KAIN, Steven, R. ,  SMITH, Thomas, H.

IPC: C07K01/22

CPC classification number: B01D15/3828 ,  B01J20/3265 ,  B01J45/00 ,  C07K1/22 ,  C07K14/43595 ,  C07K2319/21 ,  C12N9/003 ,  G01N30/02 ,  B01D15/3804

Abstract: Purification of poly-amino acid-tagged recombinant proteins has been improved by the use of a carboxymethylated aspartate ligand complexed with a third-block transition metal having an oxidation state of 2 and a coordination number of 6. A method for synthesizing the metal ion-CM-Asp complex is also described. Further, the metal ion-CM-Asp complex can be used for screening protein function.

Abstract translation: 通过使用与氧化态为2 +和配位数为6的第三嵌段过渡金属络合的羧甲基化天冬氨酸配体，提高了多氨基酸标记的重组蛋白质的纯化。 还描述了金属离子-CM-Asp复合物。 此外，金属离子-CM-Asp复合物可用于筛选蛋白质功能。

公开(公告)号：WO1997011090A1

公开(公告)日：1997-03-27

申请号：PCT/US1996014512

申请日：1996-09-17

Applicant: WEISZ, Paul, B.

IPC: C07K01/22

CPC classification number: A61K31/335 ,  A61K31/395 ,  A61K31/57 ,  A61K31/70 ,  A61K31/724 ,  A61K31/737 ,  A61K35/32 ,  A61K47/6951 ,  A61L15/28 ,  A61L26/0023 ,  A61L27/20 ,  A61L27/34 ,  A61L27/54 ,  A61L33/0005 ,  A61L2300/222 ,  A61L2300/406 ,  A61L2300/408 ,  A61L2300/416 ,  A61L2300/802 ,  B82Y5/00 ,  C07K1/18 ,  C07K2/00 ,  C07K14/50 ,  C07K14/503 ,  C08B37/0012 ,  A61K2300/00 ,  C08L5/16

Abstract: Anti-angiogenic protein composition can be prepared simply and efficiently by contacting cartilage particles containing the protein together with an electrolyte solution and an oligosaccharide bearing a minimum number of anionic substituents per sugar unit, to extract the anti-angiogenic protein from the cartilage particles and to form a complex of the oligosaccharide and the protein. The resultant anti-angiogenic complex can be used for therapeutic treatment of various angiogenic and related diseases.

Abstract translation: 通过使包含蛋白质的软骨颗粒与电解质溶液和每个糖单元具有最少数量的阴离子取代基的寡糖接触，可以简单有效地制备抗血管生成蛋白质组合物，以从软骨颗粒提取抗血管生成蛋白质， 形成寡糖和蛋白质的复合物。 所得抗血管生成复合物可用于治疗各种血管生成和相关疾病。

公开(公告)号：WO1995034576A1

公开(公告)日：1995-12-21

申请号：PCT/US1995007091

申请日：1995-06-05

Applicant: PANORAMA RESEARCH, INC.

Inventor： PANORAMA RESEARCH, INC. ,  WRIGHT, Susan, C. ,  LARRICK, James, W.

IPC: C07K01/22

CPC classification number: C12N9/6421 ,  A61K38/00 ,  Y10S514/01

Abstract: A 24 kilodalton cytoplasmic protease which cleaves at proline-valine bonds is purified from UV-induced human U937 histiocytic lymphoma cells by affinity chromatography using the inhibitor DK120 as the ligand, followed by heparin-sepharose chromatography and reverse phase HPLC. Treating nuclei of uninduced U937 cells with the affinity-purified protease is sufficient to activate internucleosomal DNA fragmentation characteristic of apoptosis as demonstrated by gel electrophoresis in the figure.

Abstract translation: 通过使用抑制剂DK120作为配体的亲和层析，然后用肝素 - 琼脂糖层析和反相HPLC，从UV诱导的人U937组织细胞淋巴瘤细胞中纯化从脯氨酸 - 缬氨酸键切割的24千道尔顿胞质蛋白酶。 用亲和纯化的蛋白酶处理未诱导的U937细胞的细胞核足以激活核糖体DNA断裂特征的细胞凋亡，如图中凝胶电泳所证实的。

公开(公告)号：WO1998005680A1

公开(公告)日：1998-02-12

申请号：PCT/EP1997004195

申请日：1997-08-01

Applicant: SEEGER, Stefan

IPC: C07K01/22

CPC classification number: C07K1/22 ,  B01D15/00

Abstract: The invention concerns a process and a device for preparing molecules. Generally, the preparation of molecules is subject to statistical variations in the number of molecules to be prepared. According to the invention, this problem is overcome in that the molecules to be prepared are applied with a high degree of dilution to a surface such that their number can be determined precisely and they can be handled in a specific manner.

Abstract translation: 本发明描述的方法和分子的制备装置。 分子通常要经过在分子的数目统计波动的制备来制备。 根据本发明，这个问题被解决在要制备的分子在一个大的稀释被施加到表面上，从而使它们的数量必须被确定，并且它们可以特异性来处理。

公开(公告)号：WO1997017361A1

公开(公告)日：1997-05-15

申请号：PCT/SE1996001430

申请日：1996-11-06

Applicant: PHARMACIA BIOTECH AB ,  JOHANSSON, Ingemar

Inventor： PHARMACIA BIOTECH AB

IPC: C07K01/22

CPC classification number: C07K16/065 ,  B01J20/321 ,  B01J20/3212 ,  B01J20/3219 ,  B01J20/3274 ,  C07K1/22 ,  G01N33/54353 ,  Y10S530/812 ,  Y10S530/813 ,  Y10S530/814 ,  Y10S530/815 ,  Y10S530/816 ,  Y10S530/817

Abstract: A separation medium comprising a base matrix and matrix-bound groups which exhibit recombinant Protein A containing a cysteine. The groups comply with the formula: - B - X - rProtein A-cys where B is a bridge which binds to the base matrix and X includes a heteroatom N or S from rProtein A-cys. The characterizing feature is that X is thioether sulphur and/or a secondary amine (-NH-). Protein A variant characterized in that the C-terminal residue is cysteine.

Abstract translation: 一种分离培养基，其包含基质和表达含有半胱氨酸的重组蛋白A的基质结合基团。 这些基团符合以下公式：B-X-r蛋白A-cys，其中B是与基质基质结合的桥，X包括来自r蛋白A-cys的杂原子N或S。 其特征在于X是硫醚硫和/或仲胺（-NH-）。 蛋白A变体的特征在于C-末端残基是半胱氨酸。

公开(公告)号：WO1997000888A1

公开(公告)日：1997-01-09

申请号：PCT/US1996009691

申请日：1996-06-07

Applicant: CEDARS-SINAI MEDICAL CENTER

Inventor： CEDARS-SINAI MEDICAL CENTER ,  CUSHING, Susan ,  VIDRICH, Alda

IPC: C07K01/22

CPC classification number: C07K16/40 ,  C07K1/22 ,  C07K16/065 ,  Y10S435/962 ,  Y10S436/825

Abstract: In accordance with the present invention, there are provided novel methods and reagents for reducing background binding in antibody preparations having an unwanted affinity for intracellular protein(s). The invention method comprises treating an antibody preparation with permeabilized cells, then separating the antibody preparation from the permeabilized cells. The reagents are useful for reducing the level of background binding in antibody preparations. Also provided are antibody preparations that are substantially free of background binding.

Abstract translation: 根据本发明，提供了用于减少对细胞内蛋白质具有不希望的亲和力的抗体制剂中背景结合的新方法和试剂。 本发明方法包括用透化细胞处理抗体制剂，然后将抗体制剂与透化细胞分离。 这些试剂可用于降低抗体制剂中背景结合的水平。 还提供了基本上不含背景结合的抗体制剂。